BINEX Co., Ltd. (053030.KQ)
KRW 17490.0
(-3.95%)
KRW 17490.0
(-3.95%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.04 Billion KRW | -94.3% |
| 2022 | 17.17 Billion KRW | 36.21% |
| 2021 | 12.61 Billion KRW | -21.86% |
| 2020 | 16.13 Billion KRW | 43.13% |
| 2019 | 11.27 Billion KRW | 64.66% |
| 2018 | 6.84 Billion KRW | 187.46% |
| 2017 | -7.82 Billion KRW | -294.07% |
| 2016 | -1.98 Billion KRW | -131.39% |
| 2015 | 6.32 Billion KRW | 0.0% |
| 2013 | -6.24 Billion KRW | -3282.34% |
| 2012 | 196.23 Million KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -10.63 Billion KRW | -220.15% |
| 2024 Q2 | -8.26 Billion KRW | 22.34% |
| 2023 Q1 | 8.25 Billion KRW | 1914.23% |
| 2023 Q2 | 419.41 Million KRW | -94.92% |
| 2023 FY | 979.6 Million KRW | -94.3% |
| 2023 Q3 | -4.53 Billion KRW | -1181.6% |
| 2023 Q4 | -3.32 Billion KRW | 26.75% |
| 2022 Q4 | 409.94 Million KRW | -93.38% |
| 2022 Q3 | 6.18 Billion KRW | -23.92% |
| 2022 Q2 | 8.13 Billion KRW | 213.58% |
| 2022 FY | 17.17 Billion KRW | 36.21% |
| 2022 Q1 | 2.59 Billion KRW | -56.29% |
| 2021 Q1 | 4.03 Billion KRW | -2.42% |
| 2021 Q2 | -691.48 Million KRW | -117.15% |
| 2021 Q3 | 3.33 Billion KRW | 582.41% |
| 2021 Q4 | 5.93 Billion KRW | 77.93% |
| 2021 FY | 12.61 Billion KRW | -21.86% |
| 2020 Q2 | 5.25 Billion KRW | 218.01% |
| 2020 Q3 | 5.09 Billion KRW | -3.1% |
| 2020 Q4 | 4.13 Billion KRW | -18.89% |
| 2020 FY | 16.13 Billion KRW | 43.13% |
| 2020 Q1 | 1.65 Billion KRW | -53.69% |
| 2019 Q4 | 3.57 Billion KRW | 41.51% |
| 2019 Q2 | 3.63 Billion KRW | 133.96% |
| 2019 Q1 | 1.55 Billion KRW | -74.14% |
| 2019 FY | 11.27 Billion KRW | 64.66% |
| 2019 Q3 | 2.52 Billion KRW | -30.51% |
| 2018 Q2 | -826.03 Million KRW | 13.33% |
| 2018 FY | 6.84 Billion KRW | 187.46% |
| 2018 Q4 | 6 Billion KRW | 128.57% |
| 2018 Q3 | 2.62 Billion KRW | 417.87% |
| 2018 Q1 | -953.09 Million KRW | 61.58% |
| 2017 FY | -7.82 Billion KRW | -294.07% |
| 2017 Q3 | -2.46 Billion KRW | 22.69% |
| 2017 Q2 | -3.18 Billion KRW | -1175.48% |
| 2017 Q4 | -2.48 Billion KRW | -0.81% |
| 2017 Q1 | 296.02 Million KRW | 111.79% |
| 2016 Q2 | 439.85 Million KRW | -28.63% |
| 2016 Q3 | -532.65 Million KRW | -221.1% |
| 2016 Q4 | -2.51 Billion KRW | -371.3% |
| 2016 FY | -1.98 Billion KRW | -131.39% |
| 2016 Q1 | 616.29 Million KRW | 202.16% |
| 2015 Q1 | 542.85 Million KRW | 0.0% |
| 2015 Q4 | -603.29 Million KRW | -126.42% |
| 2015 FY | 6.32 Billion KRW | 0.0% |
| 2015 Q3 | 2.28 Billion KRW | 168.19% |
| 2015 Q2 | 851.28 Million KRW | 56.82% |
| 2014 Q1 | 330.92 Million KRW | 107.36% |
| 2014 Q2 | 1.4 Billion KRW | 325.87% |
| 2014 Q3 | 322.82 Million KRW | -77.09% |
| 2013 Q4 | -4.49 Billion KRW | -12527.08% |
| 2013 Q1 | -1.92 Billion KRW | -286.32% |
| 2013 Q3 | 36.18 Million KRW | -74.82% |
| 2013 Q2 | 143.69 Million KRW | 107.45% |
| 2013 FY | -6.24 Billion KRW | -3282.34% |
| 2012 Q3 | -1.48 Billion KRW | 0.0% |
| 2012 Q4 | 1.03 Billion KRW | 169.85% |
| 2012 FY | 196.23 Million KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 100.834% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | 131.728% |
| Bioneer Corporation | 791.75 Million KRW | -31.64% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | 120.542% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | 104.147% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 103.372% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 102.957% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | 111.058% |
| Medy-Tox Inc. | 17.32 Billion KRW | 93.983% |
| Peptron, Inc. | -15.6 Billion KRW | 106.68% |
| Amicogen, Inc. | 2.05 Billion KRW | 49.31% |
| Genexine, Inc. | -41.24 Billion KRW | 102.527% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | 111.98% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 101.29% |
| ALTEOGEN Inc. | -9.73 Billion KRW | 110.704% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 98.966% |
| SillaJen, Inc. | -21.34 Billion KRW | 104.883% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 60.425% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | 105.731% |
| Genomictree Inc. | -17.3 Billion KRW | 106.023% |
| MedPacto, Inc. | -28.75 Billion KRW | 103.625% |
| D&D Pharmatech | -13.48 Billion KRW | 107.728% |
| EASY BIO,Inc. | 20.63 Billion KRW | 94.948% |
| GI Innovation, Inc. | -55.6 Billion KRW | 101.874% |